Zymedi is a clinical stage new drug development company targeting housekeeping enzymes called ARSs (aminoacyl-tRNA synthetases) to become the leading pioneer through its potential as the “Next Generation Target for Various Diseases.” Our lead asset in development ZMA001 mAb is a novel First-in-Class (FIC) program targeting one (KARS1, lysyl-tRNA synthetase) of 20 ARSs to treat various indications of interest (cardiovascular, respiratory, inflammation associated rare diseases including cancer) by controlling the inflammatory responses of monocytes and macrophages. We are currently conducting US P1 study through collaboration with NIH/NHLBI for pulmonary arterial hypertension (PAH) as our first indication. We are extremely excited and confident that our novel first-in-class programs utilizing "HOMEOS™"ARS (aminoacyl-tRNA synthetases) integrated drug discovery and development target platform technology will pave the way for next highly exciting novel biology targets for various indications of interest (dynamic multi-modality) for the years to come and we hope to be the center of this groundbreaking ARS biology targeting new drug development company.